智通财经APP讯，贝壳-W(02423)发布公告，该公司于2025年8月15日斥资396.43万美元回购64.65万股股 份，每股回购价格为6.11-6.18美元。 ...

智通财经APP获悉，富智康集团(02038)、元征科技(02488)、美亨实业(01897)、清科创业(01945)、恒生 银行(00011)、北森控股(09669)、康宁医院(02120)、百胜中国(09987)、百胜中国(09987)、贝壳- W(02423)于2025年8月15日进行了回购。其中，回购金额最大的为恒生银行(00011)，回购数量20.00 万，回购金额2264.63 万元。 | 股票名称 | 回购数 | 回购额 | 年累计回购数量(股) | 年累计回购数量/总 | | --- | --- | --- | --- | --- | | | | | | 股本 | | 恒生银行(00011) | 20.00 万 | 2264.63 万 | 220.00 万 | 0.117% | | 百胜中国(09987) | 1.79 万 | 626.17 万 | 456.82 万 | 1.230% | | 富智康集团(02038) | 35.60 万 | 547.64 万 | 351.18 万 | 0.446% | | 贝壳-W(02423) | 64.65 万 | 396.43 万 | 2405.73 万 ...

| 1). | 購回股份(或其他證券)但沒有註銷 | | 848,220 | % | USD | 5.8947 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年7月1日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | | 851,841 | % | USD | 5.8696 | | | 變動日期 | 2025年7月2日 | | | | | | 3). | 購回股份(或其他證券)但沒有註銷 | | 845,517 | % | USD | 5.9135 | | | 變動日期 | 2025年7月3日 | | | | | | 4). | 購回股份(或其他證券)但沒有註銷 | | 724,755 | % | USD | 6 | | | 變動日期 | 2025年7月7日 | | | | | | 5). | 購回股份(或其他證券)但沒有註銷 | | 658,701 | % | USD | 6.0432 | | | 變動日期 | 2025年7月8日 | | | | | | 6). | 購回股份(或其他證券)但沒有註銷 | | ...

智通财经APP讯，贝壳-W(02423)发布公告，于2025年8月14日斥资400万美元回购64.98万股。 ...

贝壳-W(02423)发布公告，于2025年8月14日斥资400万美元回购64.98万股。 ...

Group 1 - The company, Beike-W (02423.HK), announced a share buyback plan, intending to repurchase 650,000 shares at a cost of $4 million [1]

FF305 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 不同投票權架構公司普通股 | 股份類別 A | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02423 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年8月13日 | 3,430,132,293 | | 0 | | 3,430,132,293 | | 1). 其他 (請註明) | | | % | | | | | 見B部分 | | | | | | | | 變動日期 2025年8月14日 | | | | | | | | 於下列日期結束時的結存 (註5及6 ...

Core Viewpoint - Bridgewater Associates significantly increased its holdings in major US tech stocks, including Nvidia, Microsoft, Google, and Meta, while completely divesting from several Chinese stocks like Alibaba, Baidu, and JD.com [1][5]. Group 1: Holdings Changes - As of the end of Q2, Bridgewater's portfolio value rose from $21.6 billion to $24.8 billion, with 85 new positions, 206 increased positions, 164 closed positions, and 187 reduced positions [2]. - The top ten holdings at the end of Q2 included SPDR S&P 500 ETF (SPY), iShares Core S&P ETF (IVV), Nvidia, iShares Core MSCI Emerging Markets ETF (IEMG), Google A, Microsoft, Meta, Salesforce, Booking Holdings Inc (BKNG), and GE Vernova Inc (GEV) [2]. Group 2: Major Increases in Tech Stocks - Nvidia was the most significantly increased stock, with Bridgewater adding nearly 4.39 million shares, bringing total holdings to 7.23 million shares, a 154% increase from the previous quarter, making it the third-largest holding at 4.61% of the portfolio [4]. - Microsoft, Google A, and Meta also saw substantial increases, indicating Bridgewater's optimistic outlook on these AI giants [4]. Group 3: Reductions in Other Stocks - Amazon experienced a reduction of approximately 795,500 shares, a decrease of about 6%, dropping its portfolio share from 1.17% to 1.10% [4]. - Apple shares were reduced by 584,000, a 62% decrease, lowering its portfolio share from 0.97% to 0.30% [4]. - AMD also saw a reduction of 408,900 shares, a decline of nearly 18.9%, making it the 21st largest holding [4]. Group 4: Divestment from Chinese Stocks - Bridgewater completely divested from Alibaba, selling all 5.66 million shares, as well as 2.79 million shares of JD.com and 2.08 million shares of Baidu [5]. - This marks a significant reversal from Q1, where Bridgewater had increased its holdings in Alibaba and Baidu [5].

Core Insights - HHLR Advisors, a fund management platform under Hillhouse Capital, reported a total market value of $3.105 billion in its U.S. stock holdings as of the end of Q2 2025, with over 90% allocated to Chinese concept stocks, indicating a long-term bullish outlook on quality Chinese assets [1] Group 1: Holdings Overview - Eight out of the top ten holdings of HHLR are Chinese concept stocks, with Pinduoduo being the largest position, having increased by 20% year-to-date [1] - Futu Holdings has seen a remarkable year-to-date increase of 106%, reflecting strong performance among HHLR's key investments [1] - Other notable holdings include BeiGene, NetEase, Alibaba, and Legend Biotech, all of which have shown significant performance [1] Group 2: Recent Changes in Holdings - In Q2, HHLR increased its positions in Futu Holdings and Pinduoduo while partially reducing its stakes in Alibaba, Beike, and NetEase, which have experienced substantial price increases of 52% and 54% respectively year-to-date [1] - This adjustment in holdings suggests a strategy focused on locking in profits and optimizing asset allocation in a high market environment [1] Group 3: New Entrants - For the first time, Moomoo Securities entered HHLR's top ten holdings, with Hillhouse having participated in multiple financing rounds since 2021; Moomoo went public on NASDAQ in April this year, currently valued at approximately $7.5 billion [1]

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]